STXS PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

STXS ▲ +1.06% at T+20d

LONG call ✓ call won +1.06% · α vs SPY -7.92% · entry $1.88 → $1.90

Next anchor: T+60d in 21d

Last close $1.81 (close Jun 8) · -3.72% from $1.88 entry

Entry anchored
Apr 2, 04:23 PM ET
via Databento tick

T+1d

-1.60%

call -1.60% · α -1.66%

$1.85

settled 2mo ago

T+5d

+2.13%

call +2.13% · α -2.01%

$1.92

settled 8w ago

T+20d

+1.06%

call +1.06% · α -7.92%

$1.90

settled 5w ago

T+60d

—

call — · α —

—

in 21d

Price Chart

Loading chart...

Executive Summary

Stereotaxis announced FDA 510(k) clearance for its Synchrony™ system, a digital platform designed to modernize the interventional cath lab with enhanced visualization, workflow, and remote collaboration via its SynX™ cloud app. The company reiterated guidance for over $3 million in revenue this year from Synchrony placements independent of robotic systems.

Key Financial Metrics

Revenue

$3.0M

Guidance

over $3 million

maintained

Actionable Insight

The FDA clearance removes a key regulatory hurdle, enabling immediate commercial rollout. With strong physician endorsements and a clear path to $3M+ in non-robotic revenue, Synchrony could become a near-term revenue driver. Traders should monitor Q2 and Q3 revenue recognition and adoption rates at key centers like Allina Health and University Hospitals.

Key Facts

Stereotaxis received FDA 510(k) clearance for the Synchrony™ system, a 55” 4K ultra-high-definition display platform for cath labs.
Synchrony integrates and streamlines disparate lab systems with custom layouts, ultra-low latency video, and an intuitive interface.
SynX™, a HIPAA/GDPR-compliant cloud app, enables secure remote collaboration, recording, and monitoring.
The company reiterated guidance for over $3 million in revenue this year from Synchrony systems placed outside robotic sales.
Multiple leading electrophysiologists expressed strong interest in adopting the technology, citing workflow and training benefits.

Financial Impact

Over $3 million in incremental revenue expected in 2026 from Synchrony systems alone.

revenue

Risk Factors

Execution risk in scaling production and deployment of Synchrony systems.
Forward-looking statements are subject to risks including customer adoption, global economic conditions, and healthcare policy changes.

Market Snapshot

Exchange

NYSE

Sector

Electromedical & Electrotherapeutic Apparatus

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3268405

9 reports for STXS

T+1T+5T+20T+60

67% Hit rate 2 of 3 directional calls best @ T+5▲ +6.49%May 12, 2026

Filters

Reports for STXS — sortable, filterable
	Type				Now
May 12, 2026 28d ago	8-K BEARISH ★ 6/10	$1.85 $1.73	▲ +6.49%	▲ +5.33%	$1.81 (+2.16%)
May 12, 2026 28d ago	Press Release MIXED ★ 6/10	$1.85 $1.73	▼ −6.49%	▼ −5.33%	$1.81 (−2.16%)
Apr 21, 2026 7w ago	Press Release NEUTRAL ★ 3/10	$1.92 $1.86	▼ −3.13%	▼ −4.21%	$1.81 (−5.73%)
Apr 15, 2026 7w ago	8-K MIXED ★ 6/10	$2.01 $1.94	▼ −3.48%	▼ −5.12%	$1.81 (−9.95%)
Apr 15, 2026 7w ago	Press Release BULLISH ★ 7/10	$2.01 $1.94	▼ −3.48%	▼ −5.12%	$1.81 (−9.95%)
Apr 6, 2026 9w ago	Press Release BULLISH ★ 7/10	$1.88 $1.92	▲ +2.13%	▼ −2.01%	$1.81 (−3.72%)
Apr 3, 2026 9w ago	DEFA14A NEUTRAL ★ 3/10	$1.88 $1.92	▲ +2.13%	▼ −2.01%	$1.81 (−3.72%)
Mar 23, 2026 11w ago	EFFECT NEUTRAL ★ 4/10	$1.84 $1.78	▼ −3.26%	▲ +0.30%	$1.81 (−1.63%)
Mar 13, 2026 12w ago	S-3 BEARISH ★ 6/10	$1.91 $1.84	▲ +3.66%	▲ +1.62%	$1.81 (+5.24%)

US Market Status

Market Closed — Opens in 7h 19m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access